Ignite Creation Date:
2025-12-24 @ 3:54 PM
Ignite Modification Date:
2026-01-29 @ 6:24 PM
Study NCT ID:
NCT02230592
Status:
COMPLETED
Last Update Posted:
2018-07-05
First Post:
2014-08-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001008', 'term': 'Anxiety Disorders'}, {'id': 'D003865', 'term': 'Depressive Disorder, Major'}], 'ancestors': [{'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D003866', 'term': 'Depressive Disorder'}, {'id': 'D019964', 'term': 'Mood Disorders'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 19}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-11-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-07-18', 'completionDateStruct': {'date': '2016-06-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-07-03', 'studyFirstSubmitDate': '2014-08-28', 'studyFirstSubmitQcDate': '2014-08-29', 'lastUpdatePostDateStruct': {'date': '2018-07-05', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2014-09-03', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-06-16', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Ability to measure mGluR1 in brain', 'timeFrame': '3 years'}]}, 'conditionsModule': {'keywords': ['PET', 'Metabolic Glutamate Receptors', 'Brain Imaging'], 'conditions': ['Anxiety Disorder', 'Major Depressive Disorder']}, 'referencesModule': {'references': [{'pmid': '9974152', 'type': 'BACKGROUND', 'citation': 'Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev. 1999 Jan;29(1):83-120. doi: 10.1016/s0165-0173(98)00050-2.'}, {'pmid': '11414795', 'type': 'BACKGROUND', 'citation': 'Battaglia G, Bruno V, Pisani A, Centonze D, Catania MV, Calabresi P, Nicoletti F. Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Mol Cell Neurosci. 2001 Jun;17(6):1071-83. doi: 10.1006/mcne.2001.0992.'}, {'pmid': '10416961', 'type': 'BACKGROUND', 'citation': 'Bordi F, Ugolini A. Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol. 1999 Sep;59(1):55-79. doi: 10.1016/s0301-0082(98)00095-1.'}, {'pmid': '26850512', 'type': 'DERIVED', 'citation': 'Veronese M, Zanotti-Fregonara P, Rizzo G, Bertoldo A, Innis RB, Turkheimer FE. Measuring specific receptor binding of a PET radioligand in human brain without pharmacological blockade: The genomic plot. Neuroimage. 2016 Apr 15;130:1-12. doi: 10.1016/j.neuroimage.2016.01.058. Epub 2016 Feb 2.'}, {'pmid': '26514176', 'type': 'DERIVED', 'citation': 'Zanotti-Fregonara P, Xu R, Zoghbi SS, Liow JS, Fujita M, Veronese M, Gladding RL, Rallis-Frutos D, Hong J, Pike VW, Innis RB. The PET Radioligand 18F-FIMX Images and Quantifies Metabotropic Glutamate Receptor 1 in Proportion to the Regional Density of Its Gene Transcript in Human Brain. J Nucl Med. 2016 Feb;57(2):242-7. doi: 10.2967/jnumed.115.162461. Epub 2015 Oct 29.'}]}, 'descriptionModule': {'briefSummary': 'Objective:\n\nMetabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby fine-tuning the signals sent between cells to maintain balance in neuronal activity. mGluR subtype 1 (mGluR1s) are located in several brain regions, including the cerebellum, hippocampus, olfactory bulb, and basal ganglia. mGluR1 activation stimulates phospholipase C, resulting in phosphoinositide hydrolysis and increased intracellular calcium levels. Successful development of a positron emission tomography (PET) ligand to image mGlurR1 would impact clinical management of brain disorders characterized by disruptions in glutamatergic transmission, including anxiety and stress disorders, drug addiction, epilepsy, Huntington s disease, and Parkinson s disease. However, detailed study of mGluR1s has heretofore been hindered by the lack of high affinity and selective ligands for this receptor subtype.\n\nThe present protocol will evaluate the ability of a new PET ligand, \\[18F\\]FIMX, to image and quantify mGluR1 in the brain of healthy human volunteers. This protocol covers four phases:\n\n1. Phase 0: screening whole-body scan;\n2. Phase 1: kinetic brain imaging to quantify mGluR1 in brain relative to concurrent measurement of the parent radioligand in arterial plasma;\n3. Phase 2: if the tracer is successful in Phase 1, we will estimate radiation-absorbed doses of \\[18F\\]FIMX by performing whole body imaging;\n4. Phase 3: test-retest analysis of brain binding relative to concurrent measurement of the parent radioligand in arterial plasma.\n\nStudy Population:\n\nHealthy adult female and male volunteers (n=22, ages 18 to 55) will undergo brain or whole-body imaging..\n\nDesign:\n\nThis study will begin with a screening whole-body scan to confirm that the radioactivity has fairly broad distribution in several organs. For absolute quantification of mGluR1, 22 healthy controls will have brain PET imaging using \\[18F\\]FIMX and an arterial line. Up to 12 of them will have a test-retest scan. Eight additional subjects will have a whole body PET scan for dosimetry, which does not require an arterial line.\n\n\\<TAB\\>\n\nOutcome Measures\n\nTo assess absolute quantitation of mGluR1 with \\[18F\\]FIMX, we will primarily use two outcome measures: the identifiability and time stability of distribution volume calculated with compartmental modeling. In test-retest study, we will calculate the retest variability. To assess whole-body biodistribution and dosimetry of \\[18F\\]FIMX we will use the organ time-activity curves....', 'detailedDescription': 'Objective:\n\nMetabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby fine-tuning the signals sent between cells to maintain balance in neuronal activity. mGluR subtype 1 (mGluR1s) are located in several brain regions, including the cerebellum, hippocampus, olfactory bulb, and basal ganglia. mGluR1 activation stimulates phospholipase C, resulting in phosphoinositide hydrolysis and increased intracellular calcium levels. Successful development of a positron emission tomography (PET) ligand to image mGlurR1 would impact clinical management of brain disorders characterized by disruptions in glutamatergic transmission, including anxiety and stress disorders, drug addiction, epilepsy, Huntington s disease, and Parkinson s disease. However, detailed study of mGluR1s has heretofore been hindered by the lack of high affinity and selective ligands for this receptor subtype.\n\nThe present protocol will evaluate the ability of a new PET ligand, \\[18F\\]FIMX, to image and quantify mGluR1 in the brain of healthy human volunteers. This protocol covers four phases:\n\n1. Phase 0: screening whole-body scan;\n2. Phase 1: kinetic brain imaging to quantify mGluR1 in brain relative to concurrent measurement of the parent radioligand in arterial plasma;\n3. Phase 2: if the tracer is successful in Phase 1, we will estimate radiation-absorbed doses of \\[18F\\]FIMX by performing whole body imaging;\n4. Phase 3: test-retest analysis of brain binding relative to concurrent measurement of the parent radioligand in arterial plasma.\n\nStudy Population:\n\nHealthy adult female and male volunteers (n=22, ages 18 to 55) will undergo brain or whole-body imaging.\n\nDesign:\n\nThis study will begin with a screening whole-body scan to confirm that the radioactivity has fairly broad distribution in several organs. For absolute quantification of mGluR1, 22 healthy controls will have brain PET imaging using \\[18F\\]FIMX and an arterial line. Up to 12 of them will have a test-retest scan. Eight additional subjects will have a whole body PET scan for dosimetry, which does not require an arterial line.\n\n\\<TAB\\>\n\nOutcome Measures\n\nTo assess absolute quantitation of mGluR1 with \\[18F\\]FIMX, we will primarily use two outcome measures: the identifiability and time stability of distribution volume calculated with compartmental modeling. In test-retest study, we will calculate the retest variability. To assess whole-body biodistribution and dosimetry of \\[18F\\]FIMX we will use the organ time-activity curves.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': '* INCLUSION CRITERIA:\n* Age 18 to 55.\n* Able to give written informed consent.\n\nEXCLUSION CRITERIA:\n\n* Any current Axis I diagnosis.\n* Clinically significant laboratory abnormalities.\n* Positive HIV test.\n* Unable to have an MRI scan.\n* History of neurologic illness or injury with the potential to affect study data interpretation.\n* Recent exposure to radiation (i.e. PET from other research) that, when combined with this study, would be above the allowable limits.\n* Inability to lie flat on camera bed for at least two hours.\n* Pregnancy or breast feeding.\n* Able to get pregnant but does not use birth control.\n* History of drug or alcohol abuse within 6 months or a history of alcohol or drug dependence (excepting nicotine) within 3 years\n\nExclusion criteria for the dosimetry subjects are the same as reported above, with the exception of MRI contraindications, because an MRI will not be performed in these subjects.'}, 'identificationModule': {'nctId': 'NCT02230592', 'briefTitle': 'PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX', 'organization': {'class': 'NIH', 'fullName': 'National Institutes of Health Clinical Center (CC)'}, 'officialTitle': 'PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX', 'orgStudyIdInfo': {'id': '140016'}, 'secondaryIdInfos': [{'id': '14-M-0016'}]}, 'contactsLocationsModule': {'locations': [{'zip': '20892', 'city': 'Bethesda', 'state': 'Maryland', 'country': 'United States', 'facility': 'National Institutes of Health Clinical Center, 9000 Rockville Pike', 'geoPoint': {'lat': 38.98067, 'lon': -77.10026}}], 'overallOfficials': [{'name': 'Robert B Innis, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'National Institute of Mental Health (NIMH)'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Institute of Mental Health (NIMH)', 'class': 'NIH'}, 'responsibleParty': {'type': 'SPONSOR'}}}}